Market Cap€37m

Last Close €0.33

Onxeo’s proprietary platON platform is based on a unique decoy technology in the field of DNA damage repair inhibition. The compounds have been shown in preclinical studies to be synergistic with DNA breaking therapies and have an ability to reverse tumour resistance to PARP inhibitors and TKIs.

More Onxeo content >

Investment summary

Edison Investment Research is terminating coverage on Steakholder Foods (formerly known as MeaTech) (MITC), Mesoblast (MSB), Bluglass (BLG), InMed Pharmaceuticals (INM), Onxeo (ONXEO), Arcane Crypto (ARCANE) and Aberdeen Diversified Income and Growth Trust (ADIG). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Y/E Dec
Revenue (€m)
PBT (€m)
EPS (fd) (c)
P/E (x)
P/CF (x)
2019A 4.3 (9.1) (11.5) (14.98) N/A N/A
2020A 1.8 (7.2) (8.2) (12.26) N/A N/A
2021E N/A N/A N/A N/A N/A N/A
2022E N/A N/A N/A N/A N/A N/A
Content on Onxeo
Onxeo – Edison Open House interview
Healthcare | Edison TV | 3 February 2021
Onxeo – executive interview
Healthcare | Edison TV | 15 December 2020
Onxeo – Progress with both REVOCAN and DRIIV-1b trials
Healthcare | research Update | 18 November 2020
View more
Register to receive research on Onxeo as it is published
Share price graph
Balance sheet
Forecast net debt (€m) N/A
Forecast gearing ratio (%) N/A
Price performance
Actual (2.6) (4.3) (42.1)
Relative* (9.9) (9.8) (39.0)
52-week high/low €0.6/€0.3
*% relative to local index
Key management
Judith Greciet CEO
Nicolas Fellmann CFO
Valérie Leroy Director, Investor Relations & Corporate Com